Diabetes
News
Link between low co-pays for new diabetes drugs and patient adherence
Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists in U.S. patients with type 2...
News
FDA approves cognitive-behavioral app for adults with type 2 diabetes
The app will be available to patients exclusively by prescription, with a planned 90-day use duration.
Conference Coverage
Education before Ramadan key to safe fasting with diabetes
“With correct advice and support” from knowledgeable health care professionals “most people with type 2 diabetes can fast safely during Ramadan...
Conference Coverage
COORDINATE-Diabetes: A ‘wake-up call’ for many specialties
“I look at COORDINATE as a wake-up call to the need for multispecialty approaches to people with type 2 diabetes and cardiovascular disease.”
Conference Coverage
Once-weekly basal insulin nears market for type 2 diabetes
“I feel that weekly insulins have the potential to become transformational as preferred options for basal insulin replacement in people with type...
Conference Coverage
Children with type 2 diabetes face dire complications as young adults
Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the...
Sponsored Supplement
Managing Hypoglycemia in Primary Care
Conference Coverage
OASIS and PIONEER PLUS support high-dose oral semaglutide
OASIS-1 showed that “oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer...
Conference Coverage
‘Striking’ benefit of lipid lowering in primary prevention
“If patients can’t tolerate a statin, then treat them with bempedoic acid. The bottom line is that these patients just need to be treated.”
Conference Coverage
SURMOUNT-2: Tirzepatide rings up major weight loss in type 2 diabetes
Taken together, results from SURMOUNT-1 and SURMOUNT-2 appear to make a good case for a weight-loss indication that will not depend on whether a...
News
FDA OKs empagliflozin for children with type 2 diabetes
This approval represents only the second oral treatment option for children and adolescents with type 2 diabetes after metformin.